New injection aims to tame kidney disease
NCT ID NCT06830395
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 2 study tests an injectable drug called CM313 in 106 adults with IgA nephropathy, a kidney disease that can lead to kidney failure. The goal is to see if CM313 is safe and can help control the disease by reducing kidney damage. Participants will receive either CM313 or a placebo, and researchers will monitor side effects and kidney function over time.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- CM313 injection
- What this could lead to
- If successful, this could lead to a new treatment option that slows or stops kidney damage in people with IgA nephropathy.
- What could go wrong
- This is an early Phase 2 trial with only 106 participants, so results may not apply to everyone. The drug may cause side effects or fail to show benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Mapping the Real-World treatment landscape for IgA nephropathy
- A simple test could forecast kidney disease progression
- Experimental drug aims to protect kidneys in inflammatory diseases
- Scientists probe kidney cell metabolism to unlock secrets of ANCA vasculitis
- Immune cell therapy takes on kidney disease
- Steroids for kidney disease: do they prevent failure Long-Term?